

Don't miss out Community Eye Headth Journal app today: bit.ly/CEHJ-app Volume 34 · NUMBER 113 · 2022



Update on glaucoma



Elmien Wolvaardt Editor: Community Eve Health Journal, International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK.



Victor H Hu Assistant Clinical Professor: International Centre for Eye Health, London School of Hygiene & Tropical Medicine and Consultant Ophthalmologist, Mid Cheshire NHS Hospitals, UK.

Glaucoma affects millions of people worldwide, but it is difficult to diagnose and manage.

laucoma is a major cause of irreversible blindness worldwide, and it also causes substantial disability before patients become blind. Glaucoma is difficult to detect and diagnose, and it is highly undertreated globally. In most surveys carried out in high-income countries, over 50% of people found to have glaucoma had not been diagnosed and are therefore not receiving treatment, rising to over 90% in low- and/or middle-income countries. This is because glaucoma is mostly asymptomatic until relatively late in the disease, so patients do not notice that there is a problem. In many low- and/or middle-income settings, as many as 35% of people diagnosed with glaucoma already have severe sight loss: they presented too late to benefit from interventions that may have preserved their vision.

Our aim in this issue of the Community Eye Health Journal is to provide practical articles that will help clinicians facing the challenge of providing care for glaucoma patients. Topics include glaucoma detection and diagnosis, gonioscopy (a vital examination technique), the latest guidelines for open-angle glaucoma management, and tips for managing neovascular glaucoma and the painful, blind eye. We also look at the importance of counselling and how low vision support can benefit patients with vision loss due to glaucoma.

Glaucoma is a huge topic, and this issue covers care for adults only, concentrating on open-angle disease. Many useful resources are listed on page 27 and additional articles are available only on our website and smartphone app.

Subscribe to our mailing list (www.cehjournal.org/ subscribe) to receive the updates when new articles are published online.



🖉 About this issue

Glaucoma affects millions of people worldwide, but it is difficult to diagnose and manage. In this issue, we have included practical articles to help clinicians facing the challenge of providing care to glaucoma patients. Topics include glaucoma detection and diagnosis, gonioscopy

(a vital examination technique), the latest guidelines for open-angle glaucoma management, and tips for managing neovascular glaucoma and the painful, blind eye. We also look at the importance of counselling and how low vision support can benefit patients with vision loss due to glaucoma.

Contents

1 Update on glaucoma Elmien Wolvaardt and Victor H Hu

- 2 Defining and diagnosing glaucoma: a focus on blindness prevention Jibran Mohamed-Noriega and G Chandra Sekhar
- 6 Gonioscopy skills and techniques Winnie Nolan and Adeola Onakoya
- 9 Management of chronic open-angle glaucoma Heiko Philippin
- 12 Counselling in a glaucoma care service Fatima Kyari, Heiko Philippin, Peter Shah, Hannah Faal, Sani Babayo and Mohammed Abdull
- **14** Low vision care for patients with glaucoma: there is more you can do! Karin Van Dijk, Aimbora Kristonsia Kimaro and Heiko Philippin
- **16** Neovascular glaucoma: prevention and treatment Jibran Mohamed-Noriega and Jason A Penniecook
- 18 Managing the painful blind eye Jason A Penniecook, Doris Saraí Garza Cruz and Maria Soledad Pighin Caminos
- **20 Minimum requirements for a glaucoma programme** Fatima Kyari and Rohit C Khanna
- 22 Minimally invasive glaucoma surgery (MIGS) devices: risks, benefits and suitability Francisco Otárola and Francisco Pooley
- **25 The global challenge of glaucoma** Victor H Hu
- 26 Test your knowledge: glaucoma
- 27 Picture quiz and useful resources
- 28 Key community eye health messages



VOLUME 34 • NUMBER 113• 2022 South Asia Edition







Editor Kriti Shukla editor@cehjsouthasia.org

Editorial committee

Simon Arunga João M Furtado Clare Gilbert Esmael Habtamu Fatima Kyari Ciku Mathenge Nyawira Mwange GVS Murthy Heiko Philippin Thulasiraj Ravilla Serge Resnikoff Jude Stern Sumrana Yasmin David Yorston

GLAUCOMA DEFINITION & DIAGNOSIS

Defining and diagnosing glaucoma: a focus on blindness prevention



Jibran Mohamed-Noriega Associate Professor: Department of Ophthalmology, University Hospital and Faculty of Medicine, Autonomous University of Nuevo Leon,



Mexico.

G Chandra Sekhar Vice Chair: VST Center for Glaucoma, L V Prasad Eye Institute, Hyderabad, India

Regional consultants

Hugh Taylor (WPR)

Leshan Tan (WPR)

GVS Murthy (SEAR)

Babar Qureshi (EMR)

Mansur Rabiu (EMR)

Hannah Faal (AFR)

Kovin Naidoo (AFR)

Ian Murdoch (EUR)

Janos Nemeth (EUR)

Van Lansingh (AMR)

Andrea Zin (AMR)

Wanjiku Mathenge (AFR)

Proofreading Kriti Shukla

Designing V Arun Kumar

Printing Pragati Printers

R Thulsiraj (SEAR)

A diagnostic approach that focuses on patients with definite (or clinical) glaucoma optimises the likelihood of preventing visual disability due to this potentially blinding condition.

he term glaucoma refers to a group of diseases that affect the optic nerve and could potentially lead to irreversible visual loss. Glaucomatous optic neuropathy is the hallmark of all types of glaucoma. It is characterised by deformation of the optic nerve (see Figure 1, page 4), which manifests as diffuse or focal narrowing of the neuroretinal rim and peripapillary retinal nerve fibre layer loss. The type of glaucoma, the severity of the disease, and the risk of blindness can be assessed by carrying out gonioscopy, slit lamp examination, visual field tests, and intraocular pressure (IOP) measurement.

Definitions of glaucoma

The definition of glaucoma in adults has changed over the years due to changes in our understanding of how glaucoma affects the eye, the technology available, and the

> **Consulting editor for issue 113** Victor H Hu

South Asia Editorial Board

Victor Hu Damodar Bachani Thulasiraj Ravilla Rajiv Raman Rohit C Khanna Asim Sil GVS Murthy

South Asia Advisory Committee

Victor HuBR ShamannaHans LimburgK VishwanathElizabeth KurianM Babar QureshiSara VarughesePrabhat PiyasenaMuhit MohammadNoopur GuptaSanduk RuitReeta Gurung

2 🏶 COMMUNITY EYE HEALTH JOURNAL SOUTH ASIA | VOLUME 34 | NUMBER 113 | 2022

reasons why a particular definition was constructed. A current **clinical definition** of glaucoma is: "A characteristic pattern of glaucomatous optic neuropathy (e.g., narrowing of the neuroretinal rim) with corresponding visual field defects."

Other changes related to glaucoma might be present in some patients before a clinical diagnosis is made. These may include:

- Thinning of the retinal nerve fibre layer or ganglion cell layer, which can be visualised using optical coherence tomography (OCT)
- Other functional changes such as reduced contrast sensitivity and electrophysiological abnormalities.

However, if clinically significant glaucomatous damage has occurred, then optic disc changes are normally visible, and it is very unusual that glaucoma would be diagnosed from visual field or OCT changes without disc features.

In this article, we want to propose an approach to diagnosing adults with glaucoma that is focused on preventing visual disability. With this approach, we distinguish between two groups of patients:

- Patients with **definite** (or **unequivocal**) glaucoma: those who have definite signs of glaucomatous optic neuropathy. They are at imminent risk of visual loss, usually need treatment, and must be monitored.
- Patients with suspected (or equivocal) glaucoma: those with possible signs of glaucomatous optic neuropathy. They are not at immediate risk of visual loss, at least in the short term, and usually do not need treatment, but can/must be followed up and monitored (depending on the patient).

We propose that attention is focused on patients with **definite glaucoma** as they are at greater risk of blindness and are likely to require monitoring and treatment by more experienced eye care providers.

Essential investigations

The following investigations are needed in order to determine whether a patient has definite glaucoma requiring treatment, has suspected glaucoma and also for ongoing monitoring.



Visual acuity with best correction. Although visual acuity only deteriorates at the last stages of glaucoma, measuring it on all visits is important to assess the overall visual function and rule-out other diseases.

Measuring intraocular pressure using an applanation tonometer. INDIA

Anterior segment examination using a slit lamp. This will help in the detection of secondary types of glaucoma such as pseudoexfoliation, uveitic or pigmentary glaucoma.

Anterior chamber angle assessment (including gonioscopy). This will determine whether the patient has open-angle or angle-closure glaucoma.

Examination of the optic nerve head. This is done using a slit lamp (binocularly) and a 90D or similar lens. Perform a dilated examination to rule out other retinal diseases and to make it easier to examine the optic nerve. Do this on the initial visit and yearly or if any clinical parameter (decreased visual acuity, new onset metamorphopsia etc.) changes significantly.

Visual field testing. Carry out static, automated perimetry, commonly performed using a Humphrey visual field machine.

Tonometry. Use Goldmann's applanation tonometer. Cont

Continues overleaf >

Subscribe

Visit https://bit.ly/3uwMvf5

Address for subscriptions

Community Eye Health Journal South Asia, Indian Institute of Public Health, Plot no.1, ANV Arcade, Amar Co-operative Society, Kavuri Hills, Madhapur, Hyderabad - 500033, India. **Tel** +91-40-49006000 **Email editor@cehjsouthasia.org**

Correspondence articles

We accept submissions of 800 words about readers' experiences in eye health. Contact: editor@cehjsouthasia.org Published by the International Centre for Eye Health, London School of Hygiene & Tropical Medicine.

Unless otherwise stated, authors share copyright for articles with the Community Eye Health Journal. Illustrators and photographers retain copyright for images published in the journal.

Unless otherwise stated, journal content is licensed under a Creative Commons Attribution-NonCommercial (CC BY-NC) license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial purposes, provided that the copyright holders are acknowledged. ISSN 0953-6833

Disclaimer

Signed articles are the responsibility of the named authors alone and do not necessarily reflect the views of the London School of Hygiene & Tropical Medicine (the School). Although every effort is made to ensure accuracy, the School does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the School in preference to others of a similar nature that are not mentioned. The School does not endorse or recommend products or services for which you may view advertisements in this Journal.



Optional investigations

These additional investigations or tests can be performed if needed and if the equipment is available.

Measuring central corneal thickness. This can improve the accuracy of measurements using Goldmann's applanation tonometer because this method overestimates IOP in patients with thick corneas and underestimates it in those with thin corneas. However, nomograms to 'correct' the IOP tend to be inaccurate at an individual level and are not recommended. A thin central cornea might influence the decision if the target IOP is reached in a patient with progressive disease, as the actual IOP is likely to be higher than measured.

Optical coherence tomography (OCT). This can help in the examination of the optic nerve and retina. The most frequently used metrics are the average thickness of the circumpapilar retinal nerve fibre and ganglion cell layer. However, each innovation cycle produces a different generation of devices with incompatible measurements, so the results cannot be compared for long-term follow-up assessments.

Corneal hysteresis. This non-contact tonometry technique also assesses the corneal biomechanical response and may prove to be helpful for glaucoma assessment.

Characteristics of definite glaucoma After an initial or single examination

The characteristics of a **definite** or unequivocal diagnosis of glaucoma and/or where intervention might be needed, **after an initial or single examination** include:

- 1 Focal complete loss of the neuroretinal rim. The disc damage likelihood scale (DDLS) is a good way of grading the optic disc.¹
- 2 DDLS stage ≥ 6 .
- 3 Cup-to-disc ratio > 0.8.
- 4 Focal narrowing of the neuroretinal rim, with a corresponding visual field defect. It is important to identify if the sector of the optic nerve that is affected corresponds to the location of the VF defect. Representations of the structure-function relationship, such as the Garway-Heath map, help clinicians identify if the damaged sector of the neuroretinal rim is affecting the corresponding visual field locations (Figure 2).
- 5 IOP > 35 mm Hg is not diagnostic of glaucoma, but almost all patients with this IOP level need IOP-lowering interventions. A high IOP in the absence of disc damage may be seen in patients with a secondary glaucoma or primary angle closure disease. Over-estimation of the IOP should be considered, e.g., a non-contact tonometer used or a very thick cornea. It is recommended to repeat the measurement before initiating treatment.

Figure 1 Different forms of glaucomatous optic neuropathy. **A** Enlarged CDR. **B** Focal superior disc rim narrowing. **C** Diffuse loss of the inferior disc rim. **D** Inferotemporal thinning of the disc rim and retinal nerve fibre layer defect.



UNUMUUS UNIVERSITY OF NUEVU LEON (UANL), MEXICO CC BY-NU

After consecutive examinations

On follow-up examination, the following signs of progression would confirm an unequivocal or definite diagnosis of glaucoma:

- 1 Progression of a **visual field defect** that corresponds to a location of narrow neuroretinal rim or retinal nerve fibre layer loss.
- 2 Progression of **glaucomatous optic neuropathy:**
 - Enlargement of the vertical cup-disc ratio > 0.2
 - Increase in DDLS > 2 stages
 - Increased narrowing of the neuroretinal rim (change in a sector of the neuroretinal rim (NNR) from narrow to complete loss or from a homogeneous neuroretinal rim to a narrow sector)
 - Significant expansion of a retinal nerve fibre layer defect on OCT
 - Change in the course of vessels due to changes of the optic nerve head
 - The detection of a single new disc haemorrhage usually should not be considered sufficient to diagnose glaucoma or progression, however, they do increase the risk of developing glaucoma and visual field deterioration, particularly if they appear repeatedly.

There are other factors which need to be considered when deciding on and planning the treatment of a person with glaucoma.

Patients with confirmed glaucoma, i.e., those who are most in need of treatment, can be diagnosed using a slit lamp, tonometer and visual fields alone. Clinicians who do not have access to other instruments, such as OCT, can be reassured that their patients are receiving good care so long as they receive a good clinical examination and visual field analysis.

When to suspect glaucoma

The identification of only one of the following characteristics is not enough to confirm the diagnosis of glaucoma, but they do raise the suspicion of possible glaucoma. See Figure 1 for examples.

- Cup-to-disc ratio > 0.7 (this value applies to all disc sizes, but in small discs, a smaller cup-to-disc ratio represents greater damage than in larger discs)
- Diffuse narrowing of the neuroretinal rim
- DDLS stage ≥ 4
- Disc haemorrhages
- Retinal nerve fibre layer defects
- IOP > 24 mm Hg increases the risk for glaucoma, especially in thin corneas
- Abnormal visual field defects (remember that all the diseases that affect the visual pathway from dry eye affecting the cornea, cataracts affecting the lens, retinal changes, to cerebral strokes affecting the posterior visual pathway, can affect the visual field results)
- A reduction in the thickness of OCT parameters.

It is important to remember that an OCT scan that flags in red the thickness of the retinal nerve fibre layer, ganglion cell layer, or optic nerve head rim of a **Figure 2** Map representing the relationship between Standard Automated Perimetry visual field sectors and sections of the peripapillary OCT scan circle. This map is based on the work of Garway-Heath et al and shows the correspondence between areas of the visual field and peripapillary retinal nerve fibre layer due to the anatomical configuration of the retinal nerve fibre bundles.²



patient is not enough to diagnose glaucoma. These parameters are compared to a normative dataset that underrepresent many ethnic and age groups. Similarly, an OCT scan with all parameters in green is not enough to rule out glaucomatous optic neuropathy and should not be considered equivalent to a 'normal' optic nerve. OCT changes which, in reality, represent early glaucomatous changes, typically involve only the superior or infero-temporal neuroretinal rim or macular ganglion cell layer. These changes should usually correspond with optic disc changes seen clinically and/ or with visual field changes (Figure 2).

It is always important to exclude non-glaucomatous causes of an enlarged cup-to-disc ratio and loss of neuroretinal rim or retinal nerve fibre layers.

Glaucoma classification

After clinical or definite glaucoma is diagnosed, the two main questions for the clinician are:

1. Is this glaucoma primary or secondary?

It is important to rule out secondary glaucomas which might well carry a high risk of glaucoma blindness. These include those which could have causative treatment if identified appropriately (e.g., neovascular glaucoma) and those associated with medical

conditions (e.g., uveitic or increased episcleral pressure glaucoma) and which may even potentially be life threatening (e.g., rheumatological diseases and cavernous-carotid fistulas).

2. Is the anterior chamber angle open or closed?

Gonioscopy is critical.

The management plan of a patient with glaucoma differs significantly depending on whether the iridotrabecular angle (where aqueous drains out of the eye) is open, narrow or closed and it is vitally important to determine this with gonioscopy.

When a patient is diagnosed with definite glaucoma, it is the responsibility of all eye care providers to advise patients and family about the increased risk of glaucoma in first-degree relatives.

References

- Bayer A, Harasymowycz P, Henderer JD, Steinmann WG, Spaeth GL. Validity of a new disk grading scale for estimating glaucomatous damage: correlation with visual field damage. Am J Ophthalmol 2002;133(6):758–63.
- 2 Bizios D, Heijl A and Bengtsson B. Integration and fusion of standard automated perimetry and optical coherence tomography data for improved automated glaucoma diagnostics. BMC Ophthalmol 2011;11(20).

It is important to rule out secondary glaucomas which might well carry a high risk of glaucoma blindness."



Winnie Nolan Consultant Ophthalmologist: Moorfields Eye Hospital and Clinical Associate Professor: ICEH, London School of Hygiene & Tropical Medicine, London, UK.



Adeola Onakoya Professor of Ophthalmology; Head Glaucoma Services, Department of Ophthalmology, Lagos University Teaching Hospital/ College of Medicine, University of Lagos Lagos, Nigeria.

Gonioscopy skills and techniques

All glaucoma patients must undergo a thorough gonioscopy examination as part of their ophthalmic assessment

Gonioscopy is a technique of viewing the iridocorneal angle: the area between the iris and cornea where the trabecular meshwork is located and where aqueous humour drains out of the eye. Gonioscopy lenses are needed to view the angle, as light from this area would not otherwise reach the observer.

Gonioscopy allows the identification of structures of the anterior chamber angle and an estimation of the angle width; it is also necessary during any procedures affecting the angle, such as laser or surgery.

Anything which impedes drainage through the trabecular meshwork can cause an increase in the intraocular pressure. It is therefore critical that all potential and newly diagnosed glaucoma patients undergo a thorough gonioscopy examination as part of their ophthalmic assessment so that the mechanism of raised intraocular pressure can be established.

In this article, we will focus on a basic gonioscopy technique for the diagnosis of primary and secondary angle-closure glaucoma and for use in angle procedures.

Structures of the iridocorneal angle

From anterior (towards the cornea) to posterior (towards the iris), the structures seen are:

- Schwalbe's line. Demarcates Desecmet's membrane from the anterior trabeculum.
 It can be located by identifying the corneal wedge (Figure 1).
- 2 Non-pigmented trabecular meshwork. A pale area adjacent to Schwalbe's line which does not drain aqueous humour.
- 3 **Pigmented trabecular meshwork.** Brown/ pigmented area where aqueous humour drains from the eye; it is criticial to identify whether or not it is visible on gonioscopy.
- 4 **Scleral spur.** A narrow, dense, whitish band posterior to the trabeculum; a consistent landmark in all eyes.
- 5 **Ciliary body.** A dull, brown band posterior to the scleral spur.

Figure 1 Two photographs (A and B) and two drawings (C and D) showing the structures seen on gonioscopy of an open angle. B shows a patient with pigment dispersion where the angle is densely pigmented, especially the pigmented trabecular meshwork. Some patients may have very little pigment present (hypopigmented angle) and identifying the different structures can be challenging. The bottom left image shows a cross-section of the corresponding image on the bottom right. The corneal wedge is shown where the reflections from the inner and outer aspects of the cornea meet, showing the position of Schwalbe's line, helpful in hypopigmented angles.



Figure 2a Direct gonioscopy.



Gonioscopy lenses

Direct gonioscopy lenses (Figure 2a), such as the Swan-Jacobs lens, act as prisms and provide a direct, panoramic view of the angle. They are used for surgical procedures on the angle, with the patient lying on their back in the operating theatre.

Indirect gonioscopy lenses (Figure 2b), such as the Goldmann and Magnaview goniolenses (see the panel at the end of the article), combine a prism and a mirror to provide a reflected image of the opposite angle. Gonioscopy is carried out at the slit lamp, with the patient in a sitting position.

Gonioscopy examination technique

Some excellent videos and tutorials are freely accessible at www.gonioscopy.org

- Ensure minimal lighting in the room and a short (1 mm) slit beam to avoid artifactual opening of the angle (bright illumination will cause pupil constriction and opening of the angle).
- Instil topical anaesthesia and explain the procedure to the patient.
- Instruct the patient to keep both eyes open as this results in less squeezing of the eye to be examined.
- For less experienced practitioners, we suggest using an indirect gonioscopy lens with coupling gel as a more stable view is gained.



- Apply a coupling gel to the lens (e.g., carbomer gel).
- Instruct the patient to look up.
- Insert the inferior rim of the lens onto the surface of the eye and then quickly apply the rest of the lens rim to the globe (Figure 3).
- To make insertion easier, the forefinger of the hand inserting the lens can be used to pull the lower lid down and if necessary, the thumb of the other hand to elevate the upper lid.
- Once the lens is in, ask the patient to look straight ahead.
- View the inferior angle through the superior "A good method of mirror, and vice versa.
- Rotate the lens to view the nasal and temporal angles. In order to best visualise the trabecular meshwork and other angle structures, the slit beam should be at right angles to the mirror and the light offset by 30-60 degrees.

Assessing the angle width and status

First establish whether the angle is open or closed. Iridotrabecular contact (ITC) is present when it is not possible to visualise the pigmented trabecular meshwork without manipulation. A good method of locating trabecular meshwork is to identify Schwalbe's line (see Figure 1) and then move posteriorly.

locating trabecular meshwork is to identify Schwalbe's line (see Figure 1) and then move posteriorly."

Continues overleaf >

Figure 3 Insertion of an indirect gonioscopy lens using coupling gel.



Figure 4 Shaffer grading system.



Asking the patient to move the eye in the direction of the mirror, indenting the cornea, or increasing the light can all help to open the angle and visualise more posterior structures. These manoeuvres can help to differentiate between appositional angle closure as compared to synechial closure. However, grading of the angle width (how open the angle is) should be performed in dim light, with the eye in the primary position and without indentation.

There are a number of different grading systems for angle assessment (see references). In practice, a modified Shaffer grading scheme (Figure 4) is commonly used for grading the angle width. The visibility of angle structures is used:

- Grade 0. No angle structures visible.
- Grade 1. Schwalbe's line visible (i.e., the angle is essentially closed as aqueous humour is not able to drain).
- Grade 2. Pigmented trabeculum visible (aqueous able to drain but the angle is relatively narrow).



• Grade 3. Scleral spur visible.

• Grade 4. Ciliary body visible (angle is wide open).

Each guadrant (superior, inferior, nasal and temporal) should be graded. Although this is a quick and easy system it is also helpful to also estimate the angle width in degrees (Figure 5) as it provides more information on risk of future closure.

When assessing whether angle closure is present, "It is important or if the patient is at high risk of angle closure, it is important to consider the whole clinical situation (clinical history, symptoms, other examination findings, and so on). For practical purposes, if the angle width is greater than 25 degrees and scleral situation." spur is visible all the way around the angle, there is likely to be a low risk of angle closure. If pigmented trabecular meshwork cannot be seen, i.e, there is iridotrabecular contact for more than two quadrants (over half) of the angle on gonioscopy, there is likely to be a high risk of angle closure. In this situation, intervention to open the angle may be warranted, depending on the presence of other abnormalities such as raised intraocular pressure or risk factors for acute angle closure.

to consider the whole clinical

Indirect gonioscopy lenses

Goldmann and Magnaview lenses are indirect gonioscopy lenses, or goniolenses (Figure 6), which require the use of a coupling gel to fill the gap between the lens and the cornea and give a stable, undistorted view of the angle structures and configuration. These lenses have either one or two mirrors through which the observer views the angle. The Magnaview lens is larger than all the Goldmann lenses, giving more magnification and allowing a more detailed view of the angle. However, it may be difficult to insert if patients

have a small palpebral aperture. It can be used for delivering selective laser trabeculoplasty.

The Zeiss, Posner and Sussman lenses are indirect gonioscopy lenses which allow a rapid view of the entire angle without the need for a coupling gel. They can be used for indentation gonioscopy - pressure is applied on the cornea with the lens, this can help to open up the angle so that further structures can be

Figure 6 Image on the left shows a Goldmann two mirror lens, on right is a Magnaview one mirror lens



identified (such as with plateau iris syndrome). If peripheral anterior synechiae are present the angle will not open further even with indentation. The view of the angle is not as stable or clear as that with the Goldmann or Magnaview. Inadvertent indentation can result in corneal striations and distortion of the view as well as accidental opening up of the angle and misclassification of a closed angle as open.

Further reading

American Academy of Ophthalmology. https://www.aao. org/disease-review/ gonioscopic-gradingsystems

European Glaucoma Society Guidelines. https://www.eugs. org/eng/guidelines. asp

University of Iowa Health Care.

www.gonioscopy.org Evewiki. https://eyewiki.aao. org/gonioscopy



Management of chronic open-angle glaucoma

Heiko Philippin Clinical Research Fellow: International Centre for Eve Health, London School of Hygiene & Tropical Medicine, UK. Global Advisor for Inclusive Eye Health/ Research & Training: CBM, Bensheim, Germany and Glaucoma Specialist: Eve Center, Medical Center, University of Freiburg, Germany.

The rate of progression is the deciding factor in when and how to treat primary open-angle glaucoma. Treatment is complex, so it is important to consider patient and health care factors while keeping in mind the overall aim: preserving the patient's quality of life and livelihood.



Teaching patient with glaucoma how to instill eye drops, Madurai. INDIA

he purpose of glaucoma care is to preserve the quality of life and livelihood of a person with glaucoma, which includes maintaining their visual function while minimising the side-effects and complications of treatment. In order to deliver such patient-centred care, a glaucoma care system which can provide long-term, affordable, sustainable, and equitable care needs to be in place.

The objective of glaucoma treatment

A person with open-angle glaucoma is at risk of irreversible blindness. The objective of treatment is to minimise this risk, usually by lowering the intraocular pressure (IOP) so that an individual upper threshold IOP (also known as their target IOP) is not exceeded. However, we must weigh the expected long-term benefit of preserving vision against side-effects, complications, and the long-term cost of treatment – all of which can affect quality of life and the person's livelihood.

Key points

- The aim of patient-centred glaucoma care is to preserve and promote quality of life and livelihood
- The objective of treatment is to minimise the risk of irreversible vision loss
- The individual therapy plan is determined by the rate of progression of glaucoma
- Available treatments should be tailored to the person with glaucoma
- A single measurement of a high intraocular pressure (IOP) alone should not usually trigger a change of the plan
- Refer patients for low vision care, rehabilitation, and counselling as needed.

Choosing a therapy plan

An individual therapy plan is based on a detailed history, visual acuity, and examination of general and glaucoma-related structural and functional details and any changes in these (visual field, disc damage likelihood scale, etc.).

The key result from the history and examination is the rate of progression of the glaucomatous damage. This has to be determined regularly, for each eye separately, and can be divided broadly into three groups:

Group 1. Probably no progression, or only a low rate of progression.

Group 2. Insufficient information to determine the rate of progression.

Group 3. A high rate of progression of vision loss which will probably lead to vision impairment during the patient's' lifetime and might have an impact on her or his quality of life and daily activities.

If the rate of progression is low, monitoring can continue, either by only observing the eye or continuing with the same treatment (Group 1). If this was the patient's first assessment or if there is not enough information from previous examinations available, the risk for progression can be estimated (Group 2). An increased risk of glaucoma progression to visual loss is associated with advanced disease on presentation, high intraocular pressure, older age, certain ethnic groups, disc haemorrhages, and thin central corneal thickness, among others.^{1,2}

If there is an estimated high risk of progression (Group 2), or if there is actual evidence of a high rate of progression (Group 3), an escalation of treatment is indicated. However, it is important to review the current treatment before escalating the therapy;

Continues overleaf ►

e.g., first checking whether the patient was able to purchase the prescribed eye drops and whether they have actually been taking the treatment.

Lowering IOP

Lowering IOP prevents or delays the onset or progression of glaucoma. However, there is no specific IOP threshold, formula, or percentage reduction which applies to all patients. Instead, it is recommended to set and subsequently adapt an **individual target IOP**. This can be defined as the IOP that slows down the rate of progression of the glaucomatous damage enough to maintain the patient's quality of life and livelihood during their lifetime.^{1,3}

This definition contains three elements which need to be considered:

- Intraocular pressure
- Rate of progression of the glaucomatous damage
- Quality of life and livelihood.

Analysis of the advanced glaucoma intervention study (AGIS) showed that participants with IOP <18 mmHg at 100% of visits showed no visual field progression.^{4,5} However, high-quality prospective data comparing different target IOP levels are not currently available; as such, the trade-off between risks and benefits associated with different thresholds is unclear.¹ Target pressure should therefore be individualised and may need adjustment over time.¹

A single measurement of a high intraocular pressure alone should not trigger a change of management and needs to be put into the context of the other examination results and the history, including self-reported adherence. IOP may also fluctuate within hours or days so that several measurements might provide a better picture of the general level of IOP in an eye. Sometimes a repeat examination on the same day or a repeat follow-up visit within a few weeks might be helpful to decide on the next step, e.g., an escalation of treatment. This also depends on the level of urgency, which can be high for eyes with severe visual field loss and a high rate of progression.

There are several treatment options available to reduce IOP. They can be divided in three groups: medical treatment (usually eye drops but may include oral or intravenous medication, e.g., acetazolamide), laser and surgery. Current cost-effective examples are timolol eye drops, selective laser trabeculoplasty, and trabeculectomy. Other eye drops are only available at considerably higher cost and may not be affordable for some patients in an LMIC context.⁶

Some examples are given below, but these will vary depending on the local or regional glaucoma care system.

Medical treatment

Medication (a conservative treatment) can reduce IOP by decreasing aqueous production (Table 1a) or enhancing aqueous outflow (Table 1b). Osmotic agents are not mentioned as they are not for long-term use. **Table 1a** Efficacy and side effects of glaucoma medication to decrease aqueous production

Drug	Efficacy	Side effects (selection)
β-Blockers (e.g., timolol)	+++	Bronchospasm, bradycardia, depression
Carbonic anhydrase inhibitors (systemic) (e.g., acetazolamide)	++++	Metallic taste, electrolyte imbalance
Carbonic anhydrase inhibitors (topical) (e.g., dorzolamide)	++	Stinging, burning, headache
α2-adrenergic agonists (e.g., brimonidine)	++(+)	Toxic reaction of external eye, dry mouth. Contraindicated in children

Table 1b Efficacy and side effects of glaucoma medication to enhance aqueous outflow

Drug	Efficacy	Side effects (selection)
Prostaglandin analogues (e.g. latanoprost)	+++(+)	Eyelash growth, periorbital fat atrophy, increased iris pigmentation
Rho-kinase inhibitors (e.g. netarsudil)	++(+)	Conjunctival hyperaemia, headache
Cholinergic agonists (e.g., pilocarpine)	++(+)	Headache, dim vision

Laser treatment

Laser treatment can decrease aqueous production by partial destruction of the ciliary body epithelium, which produces aqueous (Table 2a) or by increasing aqueous outflow through the trabecular meshwork (Table 2b).

 Table 2a
 Laser treatment to decrease aqueous production

Laser	Comments
Transscleral cyclophotocoagulation (TSCPC)	Typically, diode laser (810 nm) is used. Risk of irreversible hypotony. Therefore, fractional treatment is common. ⁷
Endoscopic cyclophotocoagulation	Similar to TSCPC, with a better complications profile, but more invasive.
Micropulse transscleral cyclophotocoagulation (MP-TSCPC)	Diode laser (810 nm) with short bursts instead of continuous delivery of laser energy to reduce destruction of adjacent non-ciliary tissue. Might also enhance uveoscleral outflow. ⁸

Table 2b Laser treatment to enhance aqueous outflow

Laser	Comments
Argon laser trabeculoplasty (ALT)	Initial treatment with argon laser trabeculoplasty was at least as efficacious as initial treatment with topical medication (GLT). Risk of scarring of the trabecular meshwork and peripheral anterior synechiae formation.
Selective laser trabeculoplasty (SLT)	532 nm frequency-doubled Q-switched Nd:YAG laser. Similar efficacy as ALT (LiGHT, KiGIP SLT trials) but less side effects and repeatable. ^{9,10}
Micropulse laser trabeculoplasty (MLT)	Using 810 nm, 532 nm or 577 nm lasers. Possibly similar efficacy as SLT

Surgery

There are several surgical options to reduce intraocular pressure, including a selection of minimally invasive options. 'Ab externo' refers to a surgical approach from outside the eye, often involving a conjunctival dissection and scleral incision. 'Ab interno' refers to a surgical approach from inside the eye, usually through the anterior chamber, with a corneal incision.

There are three main categories of glaucoma surgery, each with a different purpose:

- 1 To enhance aqueous outflow into the sub-Tenon space
- 2 To enhance aqueous outflow through the trabecular meshwork
- 3 To enhance aqueous outflow through the suprachoroidal space.

1. Surgery to enhance aqueous outflow into the sub-Tenon space Ab externo approach:

- **Trabeculectomy.** The gold standard, low-cost procedure to create a guarded fistula between the anterior chamber and sub-Tenon space, requires adherence to follow-up. The Moorfields safer technique (i.e., using releasable sutures), is also suitable in low-resource settings.¹¹
- Glaucoma drainage devices. Aravind Aurolab drainage implant, Ahmed valve, Baerveldt shunts (250/350), PAUL Glaucoma Implant.
- **PreserFlo Microshunt.** An aqueous shunt between the anterior chamber and sub-Tenon's space; drains more posteriorly.

Evidence for selective laser trabeculoplasty

The LiGHT trial in the UK¹⁰ showed that selective laser trabeculoplasty (SLT) as first-line treatment of ocular hypertension and primary open-angle glaucoma was safe, cost-effective and resulted in the same quality of life (after 3 years) compared to eye drops.

The Kilimanjaro Glaucoma Intervention Programme (KiGIP) SLT trial compared SLT and Timolol eye drops (with standardised counselling) in patients with moderate and advanced glaucoma in Tanzania.¹¹ After one year, SLT treatment was successful in 60.7% of eyes, and Timolol eye drops were successful in 31.3% of eyes. In the SLT group, approximately one third of eyes required one repeat session of SLT; in the Timolol group, a similar proportion needed one repeat session of counselling. Safety, acceptance, vision-related quality of life, and preservation of visual acuity were comparable in both groups after one year. Eye care units in the region using a not-for-profit eye care service model would need to treat around 500 eyes per year with SLT to cover the cost of the procedure, charging an amount similar to one year's supply of timolol eye drops.

Ab interno approach:

• XEN gel stent. A 6 mm porcine-derived gelatin tube with an inner lumen of 45 µm and outer diameter of 150 µm.

2. Surgery to enhance aqueous outflow through the trabecular meshwork

Ab externo approach:

- **Canaloplasty.** Dilation of Schlemm's canal using viscoelastics and a suture.
- **Trabeculotomy.** Accessing Schlemm's canal via a partial scleral flap. A curved probe (trabeculotome) is rotated gently into the anterior chamber to incise through the trabecular meshwork.
- **Deep sclerectomy.** Non-penetrating surgery otherwise similar to trabeculectomy.
- **Iridectomy.** Improving aqueous flow from the posterior to the anterior chamber.

Ab interno approach:

- **iStent.** A 360 µm stent with a central lumen of 80 µm implanted into the trabecular meshwork.
- **Hydrus.** A permanent, 8 mm long, slightly curved microstent to dilate Schlemm's canal.
- Goniotomy. Typically used for childhood glaucoma. The trabecular meshwork is incised under direct gonioscopic visualisation using a goniotomy knife (e.g. 25-gauge needle on a syringe).
- Kahook Dual Blade or Trabectome. Disposable ab interno trabeculectomy devices to remove parts of the trabecular meshwork.

3. Surgery to enhance aqueous outflow through the suprachoroidal space

These include:

- **STARflo**, **Gold Micro Shunt**. Implants to access the suprachoroidal space (an ab externo approach).
- **iStent supra.** A 4-mm long curved stent with a lumen of 0.165 mm inserted into the suprachoroidal space (an ab interno approach).

Focus on the patient, not just the eye

The variety of treatment options available makes it much easier to find an approach to suit the individual patient. There are many factors to consider, including those related to the individual and the health system; see the online version of this article (**bit.ly/CEHJpoag**) for more detail. It is just as important to ensure that people with glaucoma receive counselling to support their compliance with treatment and quality of life, and to refer them for low vision services and rehabilitation as needed – see the rest of this issue for more information.

References

- Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern[®]. Ophthalmology. 2021;128:P71–150.
- 2 Musch DC, Gillespie BW, Lichter PR, Niziol LM, Janz NK. Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study. The Impact of Treatment and Other Baseline Factors. Ophthalmology. 2009;116:200-207.e1.
- 3 European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021;105:1–169.
- 4 Damji KF, Behki R, Wang L, Target IOP Workshop participants. Canadian perspectives in glaucoma management: setting target intraocular pressure range. Can J Ophthalmol. 2003;38:189–97.
- 5 The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000;130:429–40.
- 6 Zhao PY, Rahmathullah R, Stagg BC, Almobarak F, Edward DP, Robin AL, et al. A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery. JAMA Ophthalmol. 2018;136:1271–9.
- 7 Abdull MM, Broadway DC, Evans J, Kyari F, Muazu F, Gilbert C. Safety and effectiveness of primary transscleral diode laser cyclophotoablation for glaucoma in Nigeria. Clin Exp Ophthalmol. 2018;46:1041-7.
- 8 Chamard C, Bachouchi A, Daien V, Villain M. Efficacy, Safety, and Retreatment Benefit of Micropulse

Transscleral Cyclophotocoagulation in Glaucoma. J Glaucoma. 2021;30:781-8.

- 9 Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Bunce C, Wormald R, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393:1505-16.
- 10 Philippin H, Matayan E, Knoll KM, Macha E, Mbishi S, Makupa A, et al. Selective laser trabeculoplasty versus 0-5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Glob Heal. 2021;9:e1589-99.
- 11 King AJ, Hudson J, Fernie G, Kernohan A, Azuara-Blanco A, Burr J, et al. Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS). BMJ. 2021;373:n1014.



Fatima Kyari Associate Professor: International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK. Consultant Ophthalmologist: College of Health Sciences, University of Abuja, Nigeria.



Heiko Philippin

Clinical Research Fellow: International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK. Global Advisor for Inclusive Eye Health/Research & Training: CBM, Bensheim, Germany and Glaucoma Specialist: Eye Center, Medical Center, University of Freiburg, Germany.



Peter Shah Consultant Ophthalmic Surgeon: University Hospitals Birmingham (UHB) NHS Foundation Trust, Birmingham, UK and President of the UK and Eire Glaucoma Society.



Hannah Faal Professor of International Eye Health: University of Calabar, Calabar, Nigeria.



Sani Babayo Senior Social Welfare Assistant Officer: National Eye Care Centre, Kaduna, Nigeria.



Mohammed Abdull Chief Consultant/ Associate Professor:

Associate Professor: Ophthalmology Department, Abubakar Tafawa Balewa University, Bauchi, Nigeria.

Counselling in a glaucoma care service

Counselling can improve the eye health and quality of life of patients with glaucoma.

laucoma patients often think that their condition is synonymous with blindness and disability, leaving them feeling worried and vulnerable. They may also develop mental health issues such as depression or anxiety. Unfortunately glaucoma patients may have mental health issues even if these concerns are addressed. The glaucoma care team must offer patients balanced information that will help them to understand their options, regain hope for their future, and take practical action to protect their eyes and vision. This support - known as counselling - will help to improve patient's quality of life.



In a typical, busy clinic, some aspects of counselling can be delivered by examining clinicians, supported by other members of the glaucoma care team. However, it is preferable to give patients access to a dedicated counsellor (who may also offer counselling about other diseases and postoperative care).

Ideally, the glaucoma care team should train someone to take on this role. The person must be approachable, be skilled at talking to patients and their families, and must understand glaucoma and its treatment. Nurses, social welfare, or community health workers could be good candidates for training as glaucoma counsellors.

It is vital that clinical personnel on the glaucoma care team are in close contact with the person responsible for counselling and that they share any relevant clinical information (about the patient) with the counsellor. This enables the counsellor to answer any questions the patients may have, and/or to ask the clinicians for more information if anything is unclear.

The purpose of counselling

Counselling can be helpful in several ways, including:

- To help patients understand their condition and accept their prognosis; this may sometimes include coming to accept that the vision they have lost cannot be restored.
- To find out what patients need or want to do and refer them to other services that may help (e.g. low vision or rehabilitation).
- To provide information and help them make a decision about treatment, such as surgery.
- To improve patients' compliance with their medical treatment (e.g. regularly instilling eye drops in the correct way).



Counselling a client with glaucoma. INDIA

Focusing on the patient and their needs

A list of information can be helpful and complimentary to counselling and is not necessarily the opposite of counselling. Counselling is, by its nature, patientcentred: the counsellor is focused on the patient, what they know and understand, what they want to do, and what they need in order to have good eye health and to live as well as they possibly can.

Patients' family members and carers should always be included in counselling and it is important to listen to them. Ask them questions and find out how they intend to help the patient to achieve her or his goals. Another reason for including family members is that suffering from vision impairment or blindness without a visible cause such as a white pupil (as in cataract) can lead to alternative explanations, e.g. laziness or curses, and this can result in the patient being stigmatised by others. Red eyes from eye drops can be mistaken for an alcohol problem, for example. Constant and expensive treatment and visits to the glaucoma care team, seemingly without improvement, may be difficult for the patient to explain.

It may be necessary to provide the same information several times, particularly shortly after diagnosis, when an asymptomatic patient may be in denial. We have to be careful, however, as providing the same information, in the same way, may not have the desired effect – patients may stop listening if the information seems over-familiar. Finding out how patients have used the information in their lives, or how it applies to them, makes for a better approach (see Table 1).

Where possible, avoid giving information that sounds like a command. For example, instead of telling a patient to "use your medication or you will go blind", ask them to tell you what they know about the consequences of not adhering to treatment. Listen carefully, then follow up by asking what they think they can do to avoid these consequences. After you have listened to the patient, reflect back to them what they have said ("So, what I heard you say is that ..."). Then you can explain further or correct any misunderstanding.

Explaining the disease

Take care not to overload patients with facts – only give information that they can understand and apply in practice. Start by asking patients what ideas they have about glaucoma and about the subject of the counselling session (e.g., their own prognosis, acceptance of a surgical procedure, or compliance with treatment), and go on from there.

Glaucoma also has a genetic component, and it is important to discuss this carefully and with great sensitivity. Knowing that glaucoma can occur in many family members is helpful as patients can encourage their relatives to come for screening. However, if glaucoma is seen as a condition that will inevitably lead to blindness and disability, there is a risk of stigma which can lead to family difficulties. For example, it could cause problems in a relationship if there are fears about passing the condition on to children. Therefore, the counsellor must be tactful and guide the discussion towards the identification of first-degree relatives, in particular.

Top tips

- Develop a rapport with the person. There should be a relationship of trust – a therapeutic relationship. Listening is vital. Allow the patient to express themselves in their own words. This is also a way of finding out how they understand the situation, and where there may be gaps in their knowledge.
- Explain the disease to them in terms that are easy to understand (see From the Field panel for an example).
- Listen to the patient. Try to understand how they see their disease and its treatment, as well as their interaction with the health system.
- Try and determine what their 'soft spots' are what matters to them? For example, their children, their job, or looking after an older relative? Explaining how adhering to treatment would benefit them and the people or things they care about, may be helpful motivation for them to take action or change their behaviour.
- You may have given them some bad news about vision that is already lost, and which may be lost in future. You must give them time and space to go through the various stages of grief: denial, anger, bargaining, depression and then acceptance. Only when they accept this can they take action.

What to ask patients	What to tell them (adapt this depending on what they have told you)	Why this is important
Can you tell me what you know about glaucoma?	Glaucoma typically develops because of increased eye pressure, often because of a reduced outflow from the eye. Reducing the eye pressure can slow down the progression.	When a patient is diagnosed with glaucoma, it often has a negative impact on their quality of life. It is important to explain the causes, how it progresses, and the patient's individual prognosis so that they are not unnecessarily anxious but will also take any treatment seriously.
What symptoms made you come to the hospital? Do you know other ways that glaucoma patients can present?	Glaucoma starts very gradually but will get worse over time – it is a progressive disease. In the early stages there may be no symptoms until there is more damage. Vision impairment, which occurs late in the disease, may be the first symptom that brings most people to hospital, but some can recognise a reduction (constriction) in their visual field and come early. Other symptoms may include dullness, aches and pain in the eyes, problems with colour vision, proneness to accidents (from stumbling on objects when walking), haloes (rainbow colours) around point light sources, etc.	Explaining to patients what the symptoms are may help them to educate others, so that people with similar symptoms may be more more likely to report to hospital early. It can also help patients to talk to their relatives and friends about their specific needs, for example the need to remove obstacles at home.
What do you know about the differences between cataract and glaucoma?	Surgery for cataract ('white' blindness) involves replacing the opaque lens (often visible to the patient) with a clear lens, and vision is restored. With glaucoma ('black blindness'), treatment (including surgery) stops the vision from getting worse. Vision that is lost cannot come back.	Glaucoma and cataract are often confused and facts about cataract might be more widely known in some regions. This article and a poster from a previous edition of this journal, can be used to explain the difference to patients. www.cehjournal. org/article/what-is-wrong-with-my-vision-and-what-can-i-do/
What, in your opinion is the aim of treatment for glaucoma?	Treatment of glaucoma does not improve vision and sometimes progression can only be slowed down. But with regular visits and treatment, vision can often be preserved. Follow-up and treatment must be pursued life-long.	Many patients expect an improvement of their vision after treatment. Without explanations, they might assume that the condition is treated with a single bottle of eye drops or may stop if a few months of treatment has not improved their sight.
Is someone else in your family having a similar problem?	Glaucoma may be more common in some families because the disease may be inherited. However, this does not mean that everyone will inevitably have it. This is why it is important for you to advise your first-degree relatives to find time and come to the hospital to check if they have glaucoma. If they come early on, we can treat them before they lose any of their sight.	A positive family history might help the patient to accept the diagnosis and family members can motivate each other to seek counselling and care. Often, a positive family history will help in reducing stigma associated with the disease as other family members have a better understanding of the problem. It also helps the family as a group to reinforce the individual's management of the disease. It is important to ensure that patients and family members understand what can be done to prevent glaucoma from resulting in vision impairment.
Do you sometimes see patterns, objects, or people that you know do not exist, or which other people don't see?	This is known as Charles-Bonnet syndrome, and people who have very advanced glaucoma can be affected. You are seeing these images because of the damage to the nerve at the back of your eyes. You may notice that the images are smaller than you would normally expect; this is typical of the syndrome, and it really is nothing to be concerned about. If you want, I will explain this to your carers and loved ones.	Symptoms of Charles-Bonnet syndrome are caused by cortical stimulation without visual input which leads to visual hallucinations (not auditory, nor olfactory) in people with advanced and end-stage glaucoma. Patients understand that the images are not real and often do not report them because they fear mental illness and possible stigmatisation. The symptoms can also be misinterpreted by those around the patients.

Table 1 Tips for explaining glaucoma to patients: what to ask them, what to tell them (depending on what they said), and why it matters.

Encouraging compliance with medical treatment

When discussing eye medication, it is important to ask the patient how often they use their medication and to invite them to demonstrate how they instil it. You can then show them the correct way to do it.

Patients' ability to instil medication correctly may be affected by several factors, e.g., arthritis of the hands, and it is important to suggest adaptations that can help them, or to train family members to do it for them. Family members can also remind the patient when it's time to instil their eye medication, which will help to improve their adherence to medication regimes and improve the effectiveness of their treatment.

The PDF of this article (www.cehjournal.org/article/ instilling-your-own-eye-drops) can be printed and given to patients as a guide.

Low vision and rehabilitation

If the patient has vision impairment, refer them for low vision services – low vision services can provide equipment and training to help them make the best use of the vision available to them. Patients may also benefit from rehabilitation services, where available, and can learn skills such as reading Braille or using a keyboard, typewriter, or other adaptive technologies.

Daily living

A counsellor can also support the patient to adapt to their condition and improve their circumstances. Instead of listing the different environmental modifications they can make, it is better to find about their present condition and how they can adapt, depending on their needs. What do they struggle with, and what do they want to be able to do? For example, finding their way from their home to a friend's house, or taking care of their physical appearance (personal grooming).

This discussion should be about concrete ideas that the patient can carry out with what they have available. You can make suggestions, but it is also important to elicit from the patient and their family members or carers what they can to achieve that change.

Patients may benefit from joining **support groups for people with glaucoma**. These are often organised by patients for patients and their relatives, and sometimes they are facilitated by eye care providers such as nurses. Here patients can learn more and share their own experience with others. They can have a positive impact on someone by, for instance, sharing techniques used in maintaining adherence to medication, procurement of medication, or adapting their environment and lifestyle. Find out what groups are available in your area and encourage patients to join them.

Peer mentoring is another useful strategy. This is where the patient is connected to another person with a similar condition to provide guidance towards developing self-help or personal grooming skills, for example.

Low vision care for patients with glaucoma: there is more you can do!

Some patients with glaucoma will experience permanent vision loss. The correct low vision advice and support will enable them to carry out their daily activities with greater ease and comfort.



Karin Van Dijk Low Vision Advisor – Global Level: CBM, Deventer, The Netherlands.



Aimbora Kristonsia Kimaro

Optometrist and Low Vision Therapist: Kilimanjaro Christian Medical Centre Eye Department, Moshi, Tanzania.



Heiko Philippin

Clinical Research Fellow: International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK. Global Advisor for Inclusive Eye Health/ Research & Training: CBM, Bensheim, Germany and Glaucoma Specialist: Eye Center, Medical Center, University of Freiburg, Germany.

People with glaucoma have specific visionrelated problems that will affect their daily activities in various ways (Table 1).¹ Learning about patients' needs and challenges is the first step in offering them useful advice on suitable interventions.

First ask questions (and observe) what your clients need and what they now find difficult when performing their daily activities. Use different tests (clinical and functional) to assess distance and near visual acuity, visual field, contrast sensitivity, and light sensitivity. The CEHJ article 'When someone has low vision' lists useful methods.² Check what support there is at home, at work, at school and in the community. This will help you to advise them on training and interventions. For example, if someone needs to be guided at night when walking to the local shop, it would be helpful to train the client and a family member or friend in a safe way of guiding.³ Remember to correct presbyopia in older patients before starting other interventions.

What interventions can help?

Here are some ideas you can suggest to your client.

- Sunglasses can help to reduce the effects of glare and improve contrast. Try a few different coloured lenses to find the ones that work best (see Case study 1, opposite).
- Improve lighting. Consider quantity, type, and direction. E.g., try a reading lamp with a flexible arm in a position that avoids creating glare.
- Ensure enough ambient lighting in dimly lit rooms and prevent large differences in lighting levels.
- Reduce glare by closing curtains or changing position so that you have less excess light.
- Add contrasting strips to steps. Line the borders of the garden with bricks painted white.
- Remove clutter and dispose of little-used items in your kitchen.
- Always carry a torch with you.
- Move closer to the TV.
- Use felt-tipped pens, which are bolder and easier to see.
- Enlarge the labels on your medication or colour code them.

Fable 1 The vision-related challenges of people with glaucomatous vision loss with examples of how daily activities may be affected. ¹		
Vision-related problems	Examples of daily activities affected	
Loss of peripheral (side) vision	Detecting people or objects only when they appear in the central visual field; bumping or stumbling into objects	
Paracentral scotomas or blurred parts	Reading is often slow and words may be missed	
Reduced ability to adapt from light to dark and dark to light	Moving around during sudden changes in lighting is more difficult	
Trouble seeing in the dark	Orientation at dusk or at night is limited	
Reduced (distance) visual acuity	Unable to recognise people in the distance (but may still see small details)	
Light sensitivity (especially to glare)	Working outside when the sun shines is difficult; cannot see well inside with glare from window light	
Impaired contrast sensitivity	Unsteady navigating on uneven terrain; tripping on steps; limited interpretation of facial expressions	

Provide (or advise the client to undergo) compensatory visual field training to enable people with visual field defects to improve navigation and avoid obstacles. For example: "Pause regularly when walking and move your head slowly up and down, then from left to right, to scan the area in front of you. For example, if you scan the area before crossing the street, you may notice a car parked on the street corner which you did not see when looking straight ahead. Then you can avoid bumping into it."



Assess for and correct presbyopia in older glaucoma patients before starting other low vision interventions. INDIA

Refer the client to appropriate peer support groups and to counselling services; these can be of real benefit to them.

Other interventions that some (but not all) people need:

- Orientation and mobility training to learn to walk using a white cane, for people who have lost all their vision or have very low visual acuity.
- Magnifiers, after refraction, correction of presbyopia and prescription of glasses has been done (see Case study 2). These can

include **optical magnifiers** (often only low to medium magnification is possible due to the limited visual field) and **smartphone apps** that magnify.⁴ A **handheld video magnifier** can offer a significantly larger field of view at a given level of magnification and contrast can be enhanced.

- Text-to-speech software, e.g., the free application 'Non-visual Desktop Access' (NVDA).⁵
 Reverse telescopes: objects look smaller so that
- more information fits into a small field of vision (only people with a good distance acuity will benefit).

References

PANJALI CHOPRA CC BY-NC-SA

- 1 Hu CX, Zangalli C, Hsieh M, Gupta L, Williams AL, et al. What Do Patients With Glaucoma See? Visual Symptoms Reported by Patients With Glaucoma. Am J Med Sci 2014;348(5):403-409.
- 2 Community Eye Health Journal issue 77, volume 25, 2012: Low vision: we can all do more. www. cehjournal.org/ low-vision-wecan-all-do-more/
- 3 RNIB. Advice on guiding a blind or partially sighted person. www.rnib. org.uk/advice/ guiding-blind-orpartially-sightedperson
- 4 https://www.aao. org/eye-health/ tips-prevention/ low-visionimpairment-appstech-assistivedevices
- 5 Screen reader reviews are available on these websites: www. everydaysight. com/best-screenreaders-for-blind/ and https:// usabilitygeek. com/10-freescreen-readerblind-visuallyimpaired-users/



Jibran Mohamed-Noriega

Associate Professor: Department of Ophthalmology, University Hospital and Faculty of Medicine, Autonomous University of Nuevo Leon (UANL), Monterrey, Mexico.



Jason A Penniecook Ophthalmologist (Glaucoma): Instituto de la Visión, Centro Mexicano de Salud Visual Preventiva, Collaborative Network for Quality in Eye Research, Montemorelos, Mexico.

Atypical causes of neovascular glaucoma

- 1 In children, retinoblastoma and Coates disease should be excluded.
- 2 If there is no retinal vein occlusion or bilateral DR, consider ocular ischaemic syndrome and ask for a Doppler ultrasound of the carotid arteries.
- 3 If all of the above are excluded, consider uveitis, other intraocular tumours, or peripheral retinal diseases.

Neovascular glaucoma: prevention and treatment

Patients with diabetic retinopathy and retinal vein occlusion are at risk of developing neovascular glaucoma, a blinding and painful condition. Early detection and prompt treatment is vital.

N eovascular glaucoma (NVG) is a devastating type of glaucoma caused when new and abnormal blood vessels block the trabecular meshwork (the tissue that drains fluid out of the eye). The formation of new blood vessels is most frequently caused by diabetic retinopathy (DR) and retinal vein occlusion. However, other atypical causes also need to be considered (see panel).



Figure 1 A diabetic patient that presented with severe pain, blurred vision and red eye. Signs of the acute stage of neovascular glaucoma are seen in this photo: ciliary injection, mild corneal epithelial oedema, and rubeosis iridis. *Top right:* An enlarged view of rubeosis iridis.

Presentation

In the early stages of this condition, patients present with symptoms of the underlying disease (diabetic retinopathy is the most common cause) such as blurred vision, floaters, or complete vision loss due to a bleed in the back of the eye (retinal or vitreous haemorrhage). As the disease progresses and the intraocular pressure (IOP) increases, patients can develop severe pain in the eye, headache, a red eye, nausea, or vomiting.

On examination, blood vessels can be seen around the pupil (rubeosis iridis); see Figure 1. Large vessels can be detected using a torch, but smaller vessels can be difficult to detect in the early stages, even when using a slit lamp. In order to detect rubeosis iridis early, it is therefore important to **examine the iris before dilation**.

The anterior chamber angle is open in the early stages of neovascular glaucoma. However, as the new vessels grow, peripheral anterior synechiae (adhesions of iris to the cornea) develop and these can close the angle, resulting in further increases in IOP. The pupil also tends to be less reactive to light and eventually progresses to a fixed, dilated pupil with abnormal curling of the more pigmented layer of the iris around the pupil margin (ectropion uveae). The new blood vessels are particularly fragile and sometimes bleed spontaneously in the anterior chamber (hyphema).

Natural history

Disease processes in the eye (DR, retinal vein occlusion, or others) trigger the production of vasoproliferative factors such as vascular endothelial growth factor (VEGF), which in turn promotes the formation of new, fragile blood vessels that are prone to leaking or bleeding. The new blood vessels (Figure 1) appear at the pupil margin and/or anterior chamber angle. Initally, the IOP is normal as the new vessels only partially block the angle; not enough to obstruct outflow and increase the IOP.

As the vessels continue to grow, aqueous outflow is reduced and the IOP increases, although the angle remains open. Eventually, contractile cells are formed and they cause the iris to adhere to the inner part of the cornea in the periphery of the iris (peripheral anterior synechiae), eventually completely obstructing the trabecular meshwork and inducing ectropion uveae at the pupillary border. The anatomical blockage of the trabecular meshwork progresses to a complete closure of the angle (the angle is drawn together like a zipper), and the IOP increases to very high levels. As a result, the corneal endothelial cells cannot maintain the cornea's transparency and corneal oedema appears, visible as a hazy cornea. The breakdown of the blood-aqueous barrier produces anterior chamber flare and inflammation is seen clinically as ciliary injection and anterior chamber cells.

The patient will experience pain, headache, nausea, and vomiting over days to weeks. The pronounced increase in intraocular pressure also damages the optic nerve, with progressive sight loss in the affected eye. In some cases, the ciliary body becomes progressively ischaemic to the point that it no longer produces aqueous humour and some eyes can then progress to phthisis bulbi (a shrunken, non-functioning eye).

In many patients with diabetes, the severity of the neovascular glaucoma may not mirror the severity of the diabetic disease seen on examination of the eye. For instance, many patients with proliferative DR may have normal IOP and no anterior segment neovascularisation. On the other hand, patients with normal visual acuity may have proliferative DR and severe neovascular glaucoma with pain as the first clinical sign that they have diabetic eye disease. Therefore, the clinicians who assess patients with diabetes or other retinal vascular diseases should be familiar with neovascular glaucoma and examine patients to assess for neovascularisation of the anterior segment. Patients with neovascular glaucoma should be referred urgently to ophthalmologists trained in treating glaucoma and the underlying retinal causes.

Detection

When examining a patient with, or suspected to have, neovascular glaucoma, ask yourself the following questions.

- 1 Is the diagnosis neovascular glaucoma, or another type of secondary glaucoma?
- 2 What is the the underlying disease that caused the neovascular glaucoma? The cause is often DR or retinal vein occlusion, but also rule out atypical causes.
- 3 How high is the IOP? It can be considered severe when the patient develops signs or symptoms of very high IOP (corneal oedema, ocular pain, or headaches).
- 4 Is the angle opened or closed? See article on gonioscopy within this issue of the journal.
- 5 What is the visual potential? It can be roughly estimated based on the severity of the macular damage caused by the underlying disease and the damage to the optic nerve caused by glaucoma.
- 6 What is the life expectancy of the patient?
- 7 Is the patient in pain or comfortable?
- 8 Are there underlying systemic diseases that require an urgent referral, such as renal failure or cancer?

Involve the other health care providers who are required to treat the patient (primary care doctor, nephrologist, cardiologist, neurologist, or nutritionist). Advise patients and carers to avoid the overuse of non-steroidal anti-inflammatories (NSAIDs) for pain relief due to the risk of gastrointestinal bleeding.

Treatment

Treatment is challenging and requires close collaboration between different health professionals. Treatment will often involve a combination of medical treatment as well as laser or surgical treatment (see Table 1).

When the angle is still open, early treatment with pan-retinal photocoagulation and intravitreal anti-VEGF may cause regression of the neovascularisation and a return of IOP to normal. On the contrary, when the angle is closed 360 degrees (zipped), almost all patients will require surgery as their natural outflow cannot be improved. Clinicians should be aware that an intravitreal injection may itself increase the eye pressure. Abrupt

reduction of IOP with a paracentesis is not advisable, due to the risk of hyphaema, vitreous haemorrhage, or decompression retinopathy.

Medical treatment

Medical treatment should include steroid, cycloplegic, and IOP-lowering eye drops. Acetazolamide is useful, but it should be prescribed carefully because many patients have renal failure and will be on multiple medications. It should also be avoided in patients with sickle cell disease.

Surgical treatment

The type of surgical management for raised IOP will depend on the visual prognosis and life expectancy. For patients with poor visual potential, an aggressive cyclodestructive procedure with cryotherapy or diode laser can effectively reduce symptoms and partially stabilise the IOP (sometimes it is easier to combine this procedure with peripheral retinal ablation using the same cryotherapy or diode laser).

For patients with good visual potential, an alternative to a cyclodestructive procedure is a glaucoma drainage device, such as an Ahmed or Baerveldt device. The choice of intervention for IOP reduction should consider the presumed life expectancy of the patient and the effects of treatment on the patient's quality of life, all costs involved (eye drops, surgery, transport, carer availability, time off work), and the patient's beliefs and preferences.

Blind eyes should only be treated to control pain (see the article on treating the painful blind eye). It should be emphasised that neovascular glaucoma secondary to DR may be asymmetrical, but tends to be bilateral. The treatment of neovascular glaucoma in the worst eye should not distract clinicians from treating the better eye with pan-retinal photocoagulation.

Table 1 Treatment of neovascular glaucoma according to clinical manifestations

Characteristics	IOP	Treatment to control IOP	Treatment to control neovascularization	
New blood vessels (rubeosis iridis) on the iris or anterior chamber angle	Normal	No		
Rubeosis iridis with an open angle	High	IOP-lowering drops, if no improvement surgery	Pan-retinal photocoagulation, retinal cryotherapy, or intravitreal anti-VEGF	
Rubeosis iridis with a closed angle	High	Surgery		
Severe neovascular glaucoma (with severe pain or IOP > 40 mmHg at presentation)	Very high	Urgent surgery to lower the IOP, such as a glaucoma drainage device or a cyclodestructive procedure. Intravitreal anti-VEGF, pan-retinal photocoagulation or retinal cryotherapy will also be needed.		
End-stage (blind) neovascular glaucoma (no perception of light)	Low to very high	Usually for pain control only, e.g., steroids and cycloplegic eye drops, as well as laser or surgery to lower the IOP.		

How to prevent neovascular glaucoma

All health care providers (doctors, nurses, technicians, nutritionists, health visitors, etc.) should encourage patients to actively control any pre-exisiting conditions, such as diabetes or hypertension.

- 1 Encourage patients with diabetes to control their blood sugar levels. Elevated blood sugar levels encourage the formation of the abnormal blood vessels.
- 2 Advise all patients to have annual eye examinations (more frequent examinations may be required).
- 3 Promptly treat severe or proliferative DR with pan-retinal photocoagulation (PRP)
- 4 In patients with retinal vein occlusion, carry out slit lamp examination and gonioscopy to monitor the anterior segment closely (monthly if ischaemic). Look out for iris or anterior chamber angle neovascularisation during the first 3-6 months.
- 5 If regular anti-VEGF intravitreal injections are used to treat DR or retinal vein occlusion, monitor the patient's eye closely for 3-6 months after treatment is stopped.
- 6 Monitor the severity of DR closely after cataract surgery, particularly if there was a posterior capsule rupture during surgery.



Managing the painful blind eye

Jason A Penniecook Ophthalmologist (Glaucoma): Instituto de la Visión, Centro Mexicano de Salud Visual Preventiva, Collaborative Network for Quality in Eye Research, Montemorelos, Mexico.



Doris Saraí Garza Cruz Ophthalmologist (Anterior Segment): Instituto de la Visión, Montemorelos/ Merida, Mexico.



Maria Soledad Pighin Caminos Ophthalmologist (Retina): Institut Català de Retina, Barcelona, Spain. Sometimes, despite all efforts to help a patient, visual function is lost permanently and the eye undergoes degenerative changes that can lead to persistent pain. Understanding that vision cannot be restored will help patients to accept suitable treatment.



Figure 1 Neovascular glaucoma often results in a painful blind eye. This eye has a collapsed anterior chamber with angle closure resulting from neovascular glaucoma secondary to proliferative diabetic retinopathy.

A lthough definitions vary widely, a working definition for a painful blind eye is one with a visual acuity of counting fingers or worse that has no realistic probability of recovering function and is accompanied by ongoing chronic pain and ongoing discomfort which has lasted for at least four weeks.

Causes of the painful, blind eye

A painful, blind eye may result from any disease that causes blindness or a phthisical (shrunken, scarred, and non-functioning) eye. Acute causes include chemical or physical trauma, and chronic conditions include corneal decompensation and advanced and intractable glaucoma, especially neovascular glaucoma.

Understanding eye pain

Mechanical, temperature, irritant and inflammation stimuli in the eye are detected by specialised nerve terminals of the trigeminal nerve (called nociceptors) which send signals to the brain in response to injury or damage in the eye tissues. These nerve terminals are part of the **peripheral nervous system**, whereas the brain and spinal cord form part of the **central nervous system**.

The signals are interpreted by the brain as different levels of discomfort, including pain, burning, or stinging, and the response can include increased tearing, blinking, protective movements, and verbal expressions.

There are two types of eye pain:

- Physiological (normal) pain resulting from damage to eye tissues. Inflammation (e.g., from uveitis) can also cause increased sensitisation of the nociceptors, resulting in persistent pain that is exaggerated in comparison to any tissue damage.^{1,2}
- Neuropathic pain resulting from damage to the nociceptors or the other structures involved in detecting, transmitting and processing pain signals

between the peripheral nervous system and the brain. This abnormal signalling response can cause sensations of discomfort and pain in response to non-painful stimuli.^{1,2}

How to manage a painful, blind eye

There are very few evidence-based approaches for managing the painful blind eye. Caregivers should try to differentiate between **physiological pain** and **neuropathic pain**, but this can be challenging.

Physiological pain. Pain that responds to anaesthetic eye drops, such as proparacaine hydrochloride, or steroid drops, implies that this is physiological pain originating in the peripheral nerves. Physiological pain can be reduced by treating the underlying cause of the pain and/or by reducing inflammation.

Neuropathic pain. Eyes that don't respond to anaesthetic drops, or steroid drops in the case of ocular inflammation, suggest a neuropathic type of pain which can be very difficult to treat. Systemic, or even psychological, interventions may be required (ideally via a specialised pain management clinic, although these are not widely available).

Whatever the cause of the pain, the most important management aim is to reduce, or help the patient cope with, the pain. Possible methods of management are outlined below. Alternatives that can be safely performed in the clinical office without the need for a surgical room are classified as "non-invasive" in this article.

Treatment of the underlying cause is important, it is also essential that the patient understands the irreversible loss of visual function; this will help when discussing some of the management options, particularly the more invasive types of treatment.

Non-invasive treatments

The first line of treatment usually consists of topical eye drops that may include lubricants, anti-inflammatory drugs (both steroidal and non-steroidal) as well as immunomodulators.

Eye drops containing **atropine** (a cycloplegic) are commonly used to reduce possible **ciliary spasm**.

A combination of **pressure-lowering**, **steroid**, **and cycloplegic drops used in the long term** can help to reduce pain for patients with a painful blind eye resulting from **neovascular glaucoma**.

Steroid drops, **lubricants** and, in some cases, **therapeutic contact lenses** are useful for patients with **corneal issues**, for example, a painful blind eye after multiple failed corneal transplants.

Retrobulbar injection of absolute (100%) alcohol to destroy the sensory ciliary nerves has also been used as a pain management option.²

Systemic drugs, including **antidepressants** and **anticonvulsants**, can be used for some types of neuropathic corneal pain. These would be given in collaboration with a family doctor or at a pain clinic.

Figure 2 Cyclocryotherapy to reduce pressure and relieve pain in a painful blind eye.



Where a **high intraocular pressure** is likely contributing to the pain, **transscleral and endocyclophotocoagulation**, **high-intensity focused ultrasound (ultrasound cycloplasty**),³ and **cyclocryotherapy**³ can be used. Destruction of the ciliary body and reduced aqueous production is the common mechanism of action and they offer the advantage of repeated treatments. Cyclocryotherapy is appropriate where vision has been lost completely.

Where the cause of the pain is a **damaged or non-healing corneal surface**, procedures such as an amniotic membrane graft or conjunctival advancement (Gunderson) flap will bring relief.

Surgical correction and even implantation of electrode devices have been used for neuropathic ocular surface-related disorders.

Evisceration (removal of the eyeball contents while leaving the sclera, the outer layer of the eyeball behind) and **enucleation** (complete removal of the eyeball) are the final alternatives that can grant definitive relief.⁴

Conclusion

An understanding of the underlying mechanism, and awareness of the different treatment options, will help direct the best approach for individual patients and achieve sustained pain relief.

Table 1 Summary

Common clinical presentations

- Following trauma (e.g., mechanical, chemical, thermal)
- Severe glaucoma, especially neovascular glaucoma (common causes include diabetic retinopathy and retinal vein occlusion)
- Endophthalmitis
- Microbial keratitis
- Uveitis

Non-invasive treatment options

- Drops to lower the intraocular pressure (if it is elevated)
- Steroid eye drops
- Oral analgesics including NSAIDs or paracetamol
- Therapeutic (bandage) contact lens for corneal surface damage
- Retrobulbar injection of alcohol or chlorpromazine
- Oral neuropathic pain medication (e.g., amitriptyline or gabapentin)

Invasive treatment options

To lower an elevated intraocular pressure:

- Transcleral or endocyclophotocoagulation
- Ultrasonic cycloplasty
- Cyclocryotherapy (when vision has been lost completely)
- Corneal protection surgery
- Amniotic membrane graft
- Conjunctival advancement flap

As a last resort: eye removal

- Evisceration
- Enucleation

References

- 1 Belmonte C, Acosta MC, Merayo-Lloves J, Gallar J. What Causes Eye Pain? Curr Ophthalmol Rep. 2015;3(2):111-121.
- 2 Bhatia J, Narayanadas B, Varghese M, Faruk M, Hafez A, Bhatia N, Bhatia A. Retrobulbar alcohol injection: a forgotten therapy for management of painful blind eye. Oman J Ophthalmol. 2018;11(2):190-191.
- 3 Ruixue W, Tao W, Ning L. A Comparative Study between Ultrasound Cycloplasty and Cyclocryotherapy for the Treatment of Neovascular Glaucoma. J Ophthalmol. 2020:4016536.
- 4 Shah-Desai SD, Tyers AG, Manners RM. Painful blind eye: efficacy of enucleation and evisceration in resolving ocular pain. Br J Ophthalmol. 2000;84(4):437-438.
- .



Fatima Kyari Associate Professor: International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK. Consultant Ophthalmologist: College of Health Sciences, University of Abuja, Nigeria.



Rohit C Khanna Network Director:

Allen Foster Eye Health Research Centre & Brien Holden Eye Centre, Gullapalli Pratibha Rao International Centre for Advancement of Rural Eye care, L V Prasad Eye Institute, Hyderabad, India.

Minimum requirements for a glaucoma programme

A successful glaucoma health care programme must provide a timely diagnosis as well as life-long monitoring and treatment of glaucoma.

laucoma is a chronic non-communicable disease. A glaucoma care service can be most effective when it considers every aspect of the care pathway: from educating the patient who did not even know about glaucoma, to the patient receiving treatment and then maintaining compliance with treatment. The authors have previously developed a conceptual framework for the glaucoma care pathway (Figure 1). The conceptual framework for an optimal glaucoma care pathway considers engaging patients in glaucoma care from the community to the hospital and imagines that patients would take certain steps to avoid blindness.¹ It takes into consideration important details about patients' experiences such as awareness, uptake of health care services, and engaging with their glaucoma care. Understanding the patient's journey will aid developing improved patient interaction processes that help promote earlier diagnosis as well as uptake of, and compliance with, treatment for glaucoma - with the aim of preventing vision loss and blindness from the disease.

The six stages needed for good glaucoma service delivery are:

- 1 Raising awareness
- 2 Access to care and earlier detection of glaucoma
- 3 Reaching/making a diagnosis

- 4 Accepting and choosing treatment
- 5 Compliance with treatment
- 6 Follow-up and monitoring to detect and treat disease progression.

All of these must be part of an integrated eye care set-up and not delivered in isolation. There is generally poor awareness of glaucoma as a potentially blinding eye condition. **Raising awareness** among the general public involves a sustained effort to educate the public and boost their knowledge about glaucoma. We suggest providing targeted and appropriate messages via:

- Mass media (e.g., radio, TV, newspapers, information leaflets, magazines, etc.)
- Social media
- Health promotional activities, such as screening for non-communicable diseases
- Special awareness sessions during global events such as World Glaucoma Week or World Sight Day
- Interactive forums, both online and in the community, where patients can learn about their condition and ask questions.

With better health education and awareness, patients can develop the confidence to accept and adhere to treatment.



Essential equipment

- 1 For basic examination: torch, visual acuity charts, ophthalmoscope, tonometer
- 2 For specialist/diagnostic examination: slit lamp, slit lamp lenses (e.g., +90D, +78D), applanation tonometer, gonioscopy lenses, pachymetry, and visual fields.
- 3 Diagnostic pharmaceuticals: anaesthetic eye drops, fluorescein, dilating eye drops, sodium hypochlorite solution for disinfection (and sterile saline as rinse), and coupling gel (e.g., methylcellulose)
- 4 Glaucoma surgical instrument set, surgical pharmaceuticals and supplies.
- 5 IOP-lowering medicines.

To improve patients' **access to care**, community and primary health care workers can be trained to identify patients with, or at risk of, glaucoma. They should also be involved in increasing awareness among patients and monitoring their compliance with treatment and follow-up. Patients at risk include older adults, first-degree relatives of patients with glaucoma, and people with high intraocular pressure (IOP). It is useful to have a family screening database (or software) to monitor first-degree relatives.

At primary level, a technician can be trained to screen for glaucoma. At the L V Prasad Eye Institute in India, at primary or vision centre level, the Van Herrick test – along with applanation tonometry readings and non-mydriatic images of optic discs – are transmitted to the telemedicine centre for glaucoma detection. Additionally, follow-up care and compliance with therapy are monitored at this level.

The **toolkit for glaucoma management in Africa**² describes the glaucoma care team according to competencies. Depending on their level of competency, members of the eye care team should be able to identify those at risk of vision loss due to glaucoma, provide care for patients with diagnosed and stable glaucoma, initiate treatment, and continue appropriate care for patients with glaucoma in order to prevent vision loss.

Other approaches to earlier detection include systematic population screening and opportunistic case-finding.

Secondary and tertiary eye care facilities should be adequately strengthened to enable them to **reach a diagnosis** of glaucoma. This requires appropriate equipment, trained, skilled personnel, and good information and management systems. Basic examination includes assessment of the optic nerve head, indentation gonioscopy for anterior chamber angle examination, measurement of central corneal thickness, visual field assessment, and optic disc imaging.

For details of equipment – refer to the IAPB essential list for glaucoma (bit.ly/IAPBglauc) which also categorises the equipment as 'essential' or 'desirable.'

Once a diagnosis of glaucoma is made, the patient and care provider are encouraged to ensure that

treatment starts as soon as possible and continues for as long as needed. The choice of treatment should be based on the risk that a patient's vision loss will progress. Consider the following:

- Stage of disease
- Sociodemographic and economic profile of the patient
- Family history of glaucoma or vision loss
- Systemic and ocular co-morbidity.

To enable **maintaining treatment** and keeping the patient in the care system, the following are important:

- Service responsiveness. This includes a pleasant hospital experience.
- Counselling. Inform the patient about the natural history of the disease, the irreversible vision loss it causes, the available interventions and purpose of treatment, and the need for long-term follow-up (including hospital visits).
 Cost of care and affordability, opportunity costs and loss of economic productivity should also be discussed.
- Patient participation in their care. The knowledge shared during counselling empowers patients to choose the most appropriate treatment through a shared decision process with the health care provider. Patient forums are also useful to encourage patients' representation and contribute to how they engage in care.³ For example, through glaucoma patients' groups and feedback, they can discuss individual concerns and suggest how the clinic/ counselling spaces are organised. Patient groups may also provide peer support, e.g. patients can talk about obtaining medicines and taking them.

Follow-up care is required for **monitoring** and optimising treatment in response to the progression of the disease. Active mechanisms for contacting patients for follow-up include the use of:

- Clear follow-up instructions and provision of appointment dates
- Keeping patients contact details for texting/ calling for reminders
- Glaucoma ambassadors volunteers within the community who encourage patients in their own care.

References

- 1 Kyari F, Chandler CI, Martin M, Gilbert CE. So let me find my way, whatever it will cost me, rather than leaving myself in darkness: Experiences of glaucoma in Nigeria. Global Health Action. 2016;9(1).
- 2 Light for the World International. A toolkit for glaucoma management in Africa [Internet]. 2021. Available from: https:// www.light-for-theworld.org/ publications/atoolkit-for-glaucomamanagement-in-subsaharan-africa/
- 3 Turakhia P, Combs B. Using Principles of Co-Production to Improve Patient Care and Enhance Value. AMA J Ethics [Internet]. 2017;19(11):1125–31. Available from: https:// journalofethics. ama-assn.org/article/ using-principles-coproduction-improvepatient-care-andenhancevalue/2017-11



Francisco Otárola Adjunct Professor of Ophthalmology: Specialty Department, Universidad de la Frontera School of Medicine, Temuco, Chile.



Pooley Adjunct Professor of Ophthalmology: University of Chile, Hospital del Salvador, Santiago, Chile.

Minimally invasive glaucoma surgery (MIGS) devices: risks, benefits and suitability

Minimally invasive glaucoma surgery (MIGS) devices can be helpful in managing intraocular pressure in the early stages of glaucoma, thereby reducing patients' reliance on medication. However, the IOP reduction tends to be small and the devices are expensive.



Figure 1 A minimally invasive glaucoma surgery device is implanted through the anterior chamber.

inimally invasive glaucoma surgery (MIGS) has emerged in the past few years as a relevant therapeutic option for glaucoma. Intraocular pressure (IOP) reduction is still the only proven treatment to halt glaucoma progression.¹ This has been traditionally achieved by both nonsurgical means (topical medications or laser therapy) and surgical means (trabeculectomy or glaucoma drainage devices). None of these methods are ideal: compliance is the main issue

for medications and surgical complications are common. The high safety profile of MIGS allows it to be used earlier than conventional types of glaucoma surgery within a glaucoma treatment plan, and is typically combined with cataract surgery in patients with mild to moderate primary open-angle glaucoma (POAG).²

MIGS usually involves the use of a small device that is inserted or placed through a clear corneal incision approached from inside the eye (ab interno).

Figure 2 A Hydrus device implanted into Schlemm's canal.



Figure 3 Testing the PreserFlo MIGS device before closing the conjunctiva.



This allows for minimal tissue disruption, a more Among favorable risk profile, and faster recovery compared clinical to conventional trabeculectomy or glaucoma drainage drop-fre

The benefit is that MIGS tends to be relatively safe and low risk. However, the IOP reduction tends to be small and there is no good evidence for their utility in low- and/or middle-income countries, where patients might be diagnosed with glaucoma at a very advanced stage.

device implantation (Figure 1).

Currently, there are many choices for the glaucoma surgeon where MIGS devices are concerned. They can be divided according to their site of action

or placement: Schlemm's canal, suprachoroidal, and subconjunctival.

1. Schlemm's canal devices

Trabectome, ELT (excimer laser trabeculotomy), iStent, iStent inject, Hydrus, and KDB (Kahook dual blade)

Schlemm's canal devices are inserted through an ab interno method with the assistance of a gonioscopic lens, aiming to increase aqueous humor outflow through the conventional pathway. Therefore, the potential effect on aqueous ouflow is influenced by the resistance provided by the episcleral venous pressure (Figure 2).

The most common procedures include the removal of trabecular tissue (Trabectome, ELT, KDB) or the implantation of a small device (iStent, iStent inject, Hydrus).

"There are a few key points to bear in mind when considering use of MIGS devices in areas of the world with limited resources for health care."

Among the products currently available, randomised clinical trial data associated the Hydrus with greater eye drop-free glaucoma control and IOP lowering than the iStent; however, these effect sizes

were small.^{3,4}

2. Suprachoroidal devices

CyPass and iStent Supra

Unlike the Schlemm's canal devices, in which aqueous outflow could be affected by episcleral venous pressure, the suprachoroidal space is a potential space that confers minimal resistance to aqueous outflow. It allows aqueous to traverse the sclera directly via the intercellular spaces between ciliary muscle febres and loose connective

tissue of the suprachoroidal space.

At present, there are no suprachoroidal devices clinically available, given that the CyPass MicroStent, despite receiving FDA approval in 2016, was withdrawn from the market after results from a post-marketing study showing accelerated endothelial cells loss.⁵ The iStent Supra is still undergoing investigation.

3. Subconjuntival devices

XEN-45 and PreserFlo Microshunt

The subconjunctival space, despite not being part of the physiological outflow pathway, is the drainage pathway most familiar to glaucoma surgeons as it is used in conventional glaucoma surgery. Just like the suprachoroidal space, the subconjunctival space is a potential site which is not limited by the episcleral venous pressure; however, aqueous drainage can be compromised by fibrosis and scarring.⁶

The XEN-45 gel stent is a biocompatible, hydrophilic tube made from porcine gelatin cross-linked with glutaraldehyde. It has been implanted using various techniques (ab-externo/ ab-interno, with or without conjunctival peritomy).

The PreserFlo Microshunt is implanted through and ab-externo approach requiring conjunctival dissection. Despite this fact, is has been classified by the FDA as a MIGS device (Figure 3).

Both devices are 'bleb-forming': designed to limit or prevent clinically significant postoperative hypotony. On the other hand, this may lead to significant scarring and device failure, the risk of which can be minimised by using antimetabolites and aggressive topical anti-inflammatory therapy in the postoperative period.

Discussion

The overall modest reduction in IOP and generally favorable safety profile of Schlemm's canal devices make it a welcome option for patients with mild or moderate glaucoma who would like to reduce their medication burden. Suprachoroidal and subconjunctival devices offer the potential of greater IOP reduction. There are no commercially available suprachoroidal devices and they are also potentially associated with unpredictable IOP spikes and hypotony. Subconjunctival devices may fail as a consequence of subconjunctival fibrosis or result in bleb-related complications.

There are a few key points to bear in mind when considering use of MIGS devices in areas of the world with limited resources for health care. Patients may present with very advanced glaucoma, and MIGS devices are likely to be less effective in these group of patients. Also, trials to date have been limited to patients with early to moderate disease.

Conventional glaucoma surgery is still the gold standard for surgical management of glaucoma, and no MIGS device has been compared head-tohead with trabeculectomy or aqueous shunt in a randomised controlled trial.

Finally, MIGS devices are relatively expensive and therefore less likely to be a practical option in countries with limited resources. Some glaucoma drainage devices cost as little as US \$50, compared to US \$400 or more for any MIGS device; this also doesn't take into account the extra cost of surgical goniolenses or the steep learning curve/training required for this type of surgery.

More prospective randomised trials, with longer follow-up periods, are required to further evaluate the efficacy and safety of this rapidly evolving field of glaucoma treatment. Further comparative studies between devices would also be helpful to evaluate their relative efficacy.

References

- 1 Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial. Lancet. 2015;385(9975): 1295-1304.
- 2 Gillmann K, Mansouri K. Minimally invasive glaucoma surgery: Where is the evidence? Asia Pac J Ophthalmol. 2020;9(3):203-214.
- 3 Otarola F, Virgili G, Shah A, Hu K, Bunce C, Gazzard G. Ab interno trabecular bypass surgery with Schlemm's canal microstent (Hydrus) for open angle glaucoma. Cochrane Database Syst Rev. 2020;2020(3).
- 4 Ahmed IIK, Fea A, Au L, et al. A Prospective Randomized Trial Comparing Hydrus and iStent Microinvasive Glaucoma Surgery Implants for Standalone Treatment of Open-Angle Glaucoma: The COMPARE Study. Ophthalmol. 2020;127(1):52-61.
- 5 Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma | Novartis. Accessed August 14, 2021. https://www. novartis.com/news/ media-releases/ alcon-announcesvoluntary-globalmarket-withdrawalcypass-micro-stentsurgical-glaucoma
- 6 Chen DZ, Sng CCA. Safety and Efficacy of Microinvasive Glaucoma Surgery. J Ophthalmol. 2017;2017.



Assistant Clinical Professor: International Centre for Eye Health, London School of Hygiene & Tropical Medicine and Consultant Ophthalmologist, Mid Cheshire NHS Hospitals, UK.

Adapted for the *Community Eye Health Journal* from Panel 5, Lancet Global Health, *Commission on Global Eye Health*, p. 519.

The global challenge of glaucoma

The *Lancet Global Health* Commission on Global Eye Health, a wide-ranging report synthesising new and existing research across many aspects of eye health, looked at the global challenges of offering glaucoma care to everyone who needs it.

laucoma is a major cause of irreversible blindness worldwide. It also results in substantial disability, even before people become blind from it, but remains undertreated globally. In most surveys carried out in high-income countries, over 50% of people found to have glaucoma had not been diagnosed and are therefore not receiving treatment. In low-income and/ or middle-income countries (LMICs), this rises to over 90%. This high percentage is because glaucoma is mostly asymptomatic until relatively late in the disease. In LMICs, as many as 35% of people diagnosed with glaucoma are already blind as a result - it is



Ophthalmologist examining the eye, Puducherry. INDIA

"Individuals need to

determine whether

be monitored to

too late for them to benefit from effective interventions that would have prevented vision loss.

Whereas cataract has a one-stop solution (cataract surgery), glaucoma requires more complex management strategies because of its chronic nature and complexity. In the absence of simple and affordable diagnostic

and treatment solutions, the global eye health community has not prioritised glaucoma; for example, when VISION 2020 was being developed more than 20 years ago. There are several crucial issues.

their glaucoma is First, there is a need to provide effective progressing so that treatments that prevent glaucoma progression and, maybe someday, treatment can be restore visual function to those with adjusted as needed." glaucomatous damage. Lowering intraocular pressure (IOP) slows, and in some cases stops, glaucoma progression, but doing so safely and effectively remains a challenge. The current treatment is often long-term topical eye drops, but poor compliance and ongoing costs are major challenges in low-resource settings. Laser trabeculoplasty, which can be administered in a single session, is an effective strategy that has shown effectiveness in such settings. Unfortunately, it rarely provides lifetime control of IOP. Although there is hope that in the future more effective surgical or laser approaches will provide safe and sustained pressure lowering, more work needs to be done.

Where to access the report: https:// globaleyehealth commission.org

Second, individuals need to be monitored to determine whether their glaucoma is progressing so that treatment can be adjusted as needed. Monitoring presents challenges for more remote and resource-limited populations, but home-based monitoring using off-the-shelf technology might become available in the near future. The growth of vision centres in India and elsewhere, staffed by mid-level ophthalmic personnel and supported remotely by ophthalmologists, is an example of how to provide ongoing monitoring

and care for people living in remote settings.

Third, affordable and effective screening approaches are needed to enable identification of individuals at risk of sight loss. Major advances in the automated grading of optic disc photographs have led to highly accurate glaucoma diagnoses on the basis of a single photo. Widespread use of screening using fundus imaging,

with artificial intelligence-assisted grading, could allow glaucoma to be diagnosed alongside the other major causes of blindness at low cost. Implementation studies are needed to determine how and where to apply these new tools.

Innovation in glaucoma detection and management could catalyse a new care model in which earlier detection and effective long-term IOP lowering, combined with remote monitoring, can prevent unnecessary blindness worldwide. To reach this goal, the global eye care community must include glaucoma in eye care planning, recognising that the patient is a central partner in its management. Many important research questions remain unresolved and require substantial investment and a concerted global effort to answer.

Test your knowledge: glaucoma

Test your understanding of the concepts covered in this issue and reflect on what you have learnt.

We hope that you will also discuss the questions with your colleagues and other members of the eye care team, perhaps in a journal club. To view the activities online, please visit: www.cehjournal.org



Tick ALL that are TRUE

Question 1

Detecting and diagnosing glaucoma, including optic nerve head examination and gonioscopy)?

- **a.** Optical coherence tomography (OCT) is essential for making a definite (unequivocal) diagnosis of glaucoma.
- **b.** Gonioscopy is an optional part of the examination of glaucoma patients.
- **c.** Loss of the superior part of the visual field (such as an arcuate scotoma) from glaucoma would usually be associated with thinning/notching of the superior part of the optic disc.
 - **d.** Many patients with glaucoma are asymptomatic and may present with irreversible vision loss in one eye.

Question 2

Neovascular glaucoma and managing the painful blind eye

- **a.** Treatment for a painful blind eye due to neovascular glaucoma may include injection of 100% alcohol into the eye to destroy the sensory ciliary nerves.
 - **b.** Non-invasive treatment options for a painful, blind eye may include atropine eye drops, steroid eye drops, and oral analgesics such as paracetamol.
- **c.** The most common causes of neovascular glaucoma are diabetic retinopathy and retinal vein occlusions.

d. Severe neovascular glaucoma is an urgent/emergency eye condition any may require intravitreal injection, pan-retinal photocoagulation (PRP) laser, and glaucoma surgery.

Question 3

Managing chronic open-angle glaucoma and running a glaucoma programme

- **a.** All glaucoma patients require treatment which may include drops, laser, or surgery.
- **b.** The purpose of glaucoma care is to preserve the quality of life and livelihood of a person with glaucoma, which includes maintaining their visual function while minimising the side-effects and complications of treatment.
- **c.** Minimally invasive glaucoma surgery is safe and effective at reducing intraocular pressure and is replacing more conventional types of glaucoma surgery (for example trabeculectomy).
- **d.** Selective laser trabeculoplasty has good evidence for its use to treat glaucoma in low- and high-income settings.

ANSWERS

- d. True. The LiGHT study in the UK and KiGIP study in Tanzania showed it was safe and effective compared to eye drops for open angle glaucoma.
- c. False. The evidence for MIGS is limited, especially in low- and middle-income settings, and they tend to give a relatively small reduction in intraocular pressure.
- b. True.
 - not be affected by the glaucoma.
- 3. a. False. Not all glaucoma patients require treatment; for example, a patient with slowly progressive disease and a short life expectancy whose quality of life will
 - d. True.
 - . True.

- b. True
- other eye if it is also affected **2.** a. False. Retrobulbar (behind the eye) injection of alcohol may be used
- c. False. A superior visual field defect would usually be associated with thinning/notching of the **inferior** part of the optic disc, and vice versa. d. True. Treatment should prevent further vision loss in that eye and the
- D. False. It is vital to identify whether there is irido-trabecular contact or angle closure in patients with glaucoma and to treat this appropriately.
- False. Glaucoma is diagnosed by observing changes to the optic disc that correspond to visual field defects. OCT is not necessary.
- 26 🗱 COMMUNITY EYE HEALTH JOURNAL SOUTH ASIA | VOLUME 34 | NUMBER 113 | 2022

Picture quiz



A 75-yearold woman presents with painless blurring of vision in the right eye for the last few months. The visual acuity is 6/60 in that eye. The photograph shows the optic disc.

Select ALL that are TRUE

Question 1

The following features can be seen in the optic disc photo

- **a.** Swelling of the optic disc
- **b.** An extremely thin optic disc rim
- c. Parapapillary atrophy
- **d.** Nasal displacement of the central retinal vessels

Question 2

Characteristics of glaucomatous optic disc include:

a. Disc haemorrhages

- **b.** Thinning of the optic disc rim, usually nasally
- **c.** Generalised/focal enlargement of the cup

Question 3

Appropriate next steps in this patient would include:

- a. A full ocular examination of both eyes including visual acuity (individual eyes), intraocular pressure measurements, examining the optic disc in the other eye and looking for secondary causes of glaucoma, such as uveitis or trauma
- b. Discharging the patient if both eyes have poor vision from advanced glaucoma as nothing more can be done
 c. Advising family members to be screened for glaucoma

ANSWERS

3. a and c. It is very important to do a full examination of both eyes. It the intraocular pressures are high they should be treated urgently. It is very important to stop further glaucomatous damage and vision loss. If patients have already developed vision loss due to glaucoma they should be given appropriate advice and support including referral to peer support groups, counselling services and access to appropriate low vision aids. Family members of glaucoma patients should be screes to appropriate low vision aids. Family members of glaucoma patients should be screened for glaucoma; this can be done by optometrists in some settings.

2. a and c. Thinning of the optic disc rim is characteristic of glaucoma, but this usually occurs at the superior and inferior poles (see article "The optic nerve head in glaucoma").

1. Answer: b, c and d. There is no optic disc swelling. This disc shows advanced glaucomatous cupping of the optic disc.

USEFUL RESOURCES

Previous articles from the *Community Eye Health Journal*

How to assess a patient for glaucoma www.cehjournal.org/article/ how-to-assess-a-patient-for-glaucoma/

Visual field testing for glaucoma – a practical guide www.cehjournal.org/article/ visual-field-testing-for-glaucoma-a-practical-guide/

Emergency management: angle-closure glaucoma www.cehjournal.org/article/ emergency-management-angle-closure-glaucoma/

Managing a patient with open-angle glaucoma: a case study www.cehjournal.org/article/managing-a-patient-withopen-angle-glaucoma-a-case-study/

Primary open-angle glaucoma: everyone's business www.cehjournal.org/article/ primary-open-angle-glaucoma-everyones-business/

'An ideal service for glaucoma would be...' www.cehjournal.org/article/ an-ideal-service-for-glaucoma-would-be/

Patients and glaucoma: what are the challenges? www.cehjournal.org/article/ patients-and-glaucoma-what-are-the-challenges/

Conversations with glaucoma patients www.cehjournal.org/article/ conversations-with-glaucoma-patients/

Guidelines

ICO Guidelines for Glaucoma Eye Care www.icoph.org/glaucoma

The European Glaucoma Society guidelines Most recent can be accessed at www.eugs.org/eng/guidelines.asp

American Academy of Ophthalmology. Preferred Practice Pattern : Primary Open Angle Glaucoma. www.aao.org/preferred-practice-pattern/ primary-open-angle-glaucoma-ppp

Online and smartphone access

Did you know that CEHJ South Asia articles are published online and on our app before the print copy becomes available?

Subscribe to our mailing list to receive an email every time a new issue is published. Visit our website at https://www.cehjsouthasia.org/

Next issue



The next issue is on the theme **Technologies in Eye Care**

Key community eye health messages

What is glaucoma?



- It refers to a group of eye conditions in which nerve fibres in the optic nerve where they leave the eye are damaged, resulting in irreversible vision loss
- Damage to the optic nerve in glaucoma is associated with high pressure in the eye
- It is usually painless, and vision loss is unnoticed until it is quite advanced.
 Therefore, regular eye health check-ups are essential to pick up glaucoma early

Essential investigations to diagnose glaucoma



- Visual acuity test to assess overall visual function and to rule out other eye diseases
- Anterior segment examination using a slit lamp
- Anterior chamber angle assessment using gonioscopy lenses
- Tonometry to measure pressure in the eye

Running a successful glaucoma program



- Spread awareness about glaucoma in the community and enhance access to early detection and care of glaucoma
- Train primary health workers to identify patients with or at risk of glaucoma
- Strengthen secondary and tertiary care facilities to enable them in reaching the diagnosis of glaucoma
- Establish referral mechanisms and facilities to prescribe low vision devices and for visual rehabilitation